Drawing for ADSIVITI

USPTO serial 97125468

ADSIVITI

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
CROWDER-SCHAEFER, ANDREW W
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ADSIVITI?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Bruce W. Longbottom

LILLY CORPORATE CENTERINDIANAPOLIS, IN 46285United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseasesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Dec 22, 2025MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Dec 22, 2025ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Aug 8, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 8, 2025EX5GSOU EXTENSION 5 GRANTED—
Aug 7, 2025AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Apr 21, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 20, 2025EXT5SOU EXTENSION 5 FILED—
Oct 28, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 28, 2024EX4GSOU EXTENSION 4 GRANTED—
Oct 28, 2024EXT4SOU EXTENSION 4 FILED—
Oct 28, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 17, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 16, 2024EX3GSOU EXTENSION 3 GRANTED—
Apr 16, 2024EXT3SOU EXTENSION 3 FILED—
Apr 16, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 18, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 16, 2023EX2GSOU EXTENSION 2 GRANTED—
Oct 16, 2023EXT2SOU EXTENSION 2 FILED—
Oct 16, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 19, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 17, 2023EX1GSOU EXTENSION 1 GRANTED—
Apr 17, 2023EXT1SOU EXTENSION 1 FILED—
Apr 17, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 15, 2022NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Sep 20, 2022NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 20, 2022PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 31, 2022NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 15, 2022CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 12, 2022DOCKASSIGNED TO EXAMINER—
Nov 19, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 18, 2021NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance